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The Discovery of Mutated Driver Pathways in
Cancer: Models and Algorithms
Junhua Zhang and Shihua Zhang
Abstract—The pathogenesis of cancer in human is still poorly understood. With the rapid development of high-throughput sequencing
technologies, huge volumes of cancer genomics data have been generated. Deciphering those data poses great opportunities and
challenges to computational biologists. One of such key challenges is to distinguish driver mutations, genes as well as pathways from
passenger ones. Mutual exclusivity of gene mutations (each patient has no more than one mutation in the gene set) has been
observed in various cancer types and thus has been used as an important property of a driver gene set or pathway. In this article, we
aim to review the recent development of computational models and algorithms for discovering driver pathways or modules in cancer
with the focus on mutual exclusivity-based ones.
Index Terms—Bioinformatics, cancer genomics, driver gene, driver pathway, mutual exclusivity, co-occurring mutation
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1 INTRODUCTION
UNDERSTANDING the mechanism of carcinogenesis hasbeen a great challenge for human. With the rapid ad-
vance in deep sequencing technologies, several large-scale
cancer projects have generated an unprecedented amount
of cancer genomics data (e.g., The Cancer Genome Atlas
(TCGA) [1], [2], the International Cancer Genome Con-
sortium (ICGC) [3], the Cancer Cell Line Encyclopedia
(CCLE) [4], and the Therapeutically Applicable Research to
Generate Effective Treatments (TARGET) [5]). The rapid ac-
cumulation of huge volumes of genomic data has provided
tremendous opportunities for the better understanding on
cancer initiation, progression and development. Decipher-
ing those data poses great challenges and computational
problems for the community of bioinformatics and com-
putational biology [6], [7], [8], [9]. For example, modeling
cancer evolution is one of such key problems. Cancer is
viewed as a somatic evolutionary process characterized by
the accumulation of mutations [10]. Evolutionary modeling
for cancer describes the dynamics of tumor cell popula-
tions and makes inference about the evolutionary history
of a tumor from molecular level [6], [11], [12]. Tumor
stratification is another fundamental issue. The key is to
classify heterogeneous tumor population into clinically and
biologically meaningful subtypes by similarity of molecular
profiles [7], [13], [14], [15]. It has been demonstrated that
tumor stratification has a profound implication for the indi-
vidualization of efficient treatments of cancer patients [13].
Similarly, distinguishing driver mutations which con-
tribute to cancer development, from passenger mutations
that have accumulated in somatic cells but without func-
tional consequences is a key challenge in computational
cancer genomics. Distinguishing drivers from passengers in
cancer can help to identify carcinogenic mechanisms and
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drug targets. In this review, we first briefly survey the
methods for identifying driver genes, and we then review
the models and algorithms of discovering driver pathways
or modules in detail with the focus on mutual exclusivity-
based ones using mutation data as well as others.
2 BRIEF SURVEY OF METHODS FOR IDENTIFYING
DRIVER GENES
A common type of methods for identifying driver genes is
based on gene mutational frequency (termed as frequency-
based methods) [16]. The basic principle of such methods is
to test individual genes whether they are mutated in a sig-
nificant number of cancer patients than expected by chance.
A key step is to estimate the background mutation rate
(BMR) to quantify the accumulation of random passenger
mutations. Proper estimation of BMR is a key factor affect-
ing the power of this type of methods. An overestimation of
BMR fails to identify true recurrent mutations (false nega-
tives), whereas an underestimation would lead to too many
false positives. Early frequency-based methods assume a
single constant background rate across the genome for all
samples [16]. However, recent studies demonstrat that BMR
is not constant across the genome [17], [18]. Moreover, a
number of features (other than mutation frequency) could
affect the mutation rate including mutation types, sequence
context [19], gene-specific features [20], [21], mutation-
specific scores that assess functional impact [22], [23], [24]
and so on.
Therefore, recent studies have developed a number of
frequency-based methods which adopt one or more of these
features to get a more accurate BMR estimation. For ex-
ample, both MuSiC [25] and MutSigCV [18] employ the
mutation types and sample-specific mutation rates. Mut-
SigCV also allows for the inclusion of gene-specific features
such as the expression level and replication timing. Youn
and Simon [17] considered mutation types and functional
impacts of mutations in their approach. Recently, Vogelstein
et al. [26] investigated the spatial patterns of mutations
2within driver genes based on an integrative analysis across
multiple cancers in COSMIC. They demonstrated that many
known oncogenes and tumor suppressors possess non-
random mutational patterns. Several methods adopt these
new features with improved sensitivity and specificity [17],
[27], [28]. OncodriveCLUST uses the evidence of positional
clustering to identify oncogenes [27]. MADGiC (Model-
based Approach for identifying Driver Genes in Cancer) is
an unified empirical Bayesian model-based approach which
uses all the above features to identify driver genes [28].
As we know, many mutations occur in different genes
among different patients. Such mutational heterogeneity in
cancer genomes is another important factor affecting the
performance of frequency-based methods. This heterogene-
ity may be a consequence of the presence of passenger mu-
tations in each cancer genome. It may also be a consequence
of the cancer evolution due to the diverse mutational events
during this process [29].
Although individual tumors exhibit diverse genomic
alterations, many studies have demonstrated that driver
mutations tend to affect a limited number of cellular signal-
ing and regulatory pathways [1], [30], [31]. Thus, a common
alternative to single gene test is to evaluate the recurrence
of mutations in groups of genes derived from known path-
ways or genome-scale gene interaction networks. These
groups of genes may be candidate driver pathways, which
may be frequently perturbed within tumor cells and can
lead to the acquisition of carcinogenic properties such as
cell proliferation, angiogenesis, or metastasis [32], [33].
Gene Set Enrichment Analysis (GSEA) can be employed
to rank the list of mutated genes first, and then assess
whether a pre-defined set of genes (such as a given path-
way) has more high-ranking genes than would be expected
by chance [34]. Depending on different scoring techniques
to rank genes, different approaches coupled with GSEA
have been used to determine enrichment of mutations in
certain pathways or cellular functions (such as CaMP-GSEA
[35]). Furthermore, considering the complex heterogeneity
of cancer genomes, several GSEA-based methods have been
presented by scoring each gene set at the patient level
rather than the gene level [36], [37]. These patient-oriented
methods are more interpretable and statistically powerful
than traditional gene-oriented methods.
It has long been realized that driver mutations or genes
perturb signaling, regulatory or metabolic pathways that
promote the development and progression of cancer. Thus,
many biological pathway or interaction network based
methods have been developed to identify significantly mu-
tated subnetworks. We have known that the mutational
landscape of cancer consists of ‘mountains’ of a few fre-
quently mutated genes and ‘hills’ of many more less fre-
quently mutated genes [26], [38]. One advantage of the
network-based methods is that it can detect less frequently
mutated driver genes which are members of gene sets
recurrently mutated [39], [40], [41]. Vandin et al. developed
a network-based method (HotNet) [40] and employed a
heat diffusion process on the interaction network to define
a local neighborhood of ‘influence’ for each mutated gene,
and then identified some recurrently mutated subnetworks
with a two-stage multiple hypothesis test. More recently,
they further extended it (HotNet2) [41] to identify pathways
and protein complexes perturbed by somatic aberrations
across multiple types of cancers. NetBox [42] and MEMo
[43] are two alternative methods. NetBox was developed
based on the detection of closely connected network mod-
ules or communities. Notably, MEMo uses the strategy of
mutual exclusivity of gene mutations to detect mutated
subnetworks critical to carcinogenesis [43].
The mutual exclusivity phenomenon that each patient
has no more than one mutation in a gene set was observed
in various cancer types [44]. For example, the mutation of
TP53 and the copy number amplification of MDM2 seldom
appear simultaneously in glioblastoma multiforme (GBM)
patients (p53 pathway) [1], and BRCA1/2 mutations and
BRCA1 epigenetic silencing in serous ovarian cancer possess
the similar property [2]. It has been commonly thought that
mutually exclusive genomic events provide strong genetic
evidence that the altered genes are functionally linked in
a common biological pathway. Therefore, many approaches
based on mutual exclusivity have been developed to iden-
tify driver pathways or core modules in recent years (Fig. 1).
3 METHODS FOR IDENTIFYING DRIVER PATHWAYS
In this section, we review the methods for identifying driver
pathways from three aspects: individual driver pathway,
cooperative driver pathways and driver pathways across
multiple types of cancers (pan-cancer level) (Table 1). Prior
knowledge-based and de novo identification methods are
two major types for identifying driver pathways.We first in-
troduce the simple mutual exclusivity-based pairwise search
for mutational patterns (PSMP) [44], which provides the
basis for understanding many other methods.
3.1 PSMP
Yeang et al. [44] examined the patterns of somatic mutations
of cancers obtained from COSMIC in 45 different tissue
types. They categorized the mutational patterns of multiple
genes into two types in terms of co-occurrence and mutual
exclusivity. They adopted the likelihood ratio (LR) statistic
between the empirical frequency of co-occurrence and its
expected frequency to test the combinatorial patterns of
gene mutations. That is, for two genes g1 and g2, the statistic
was defined as
P (gm
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m
2 ) indicates the
gene g1 (g2) is mutated and a low score suggests mutual
exclusivity and a high score indicates co-occurrence of two
given genes, respectively.
They obtained 105 significant combinatorial mutational
patterns, which cover genes in six major pathways relevant
to cancer including cell cycle control, stress response, Ras,
insulin growth factor (IGF-AKT), Wnt, and TGF-β signal-
ing pathways. Most co-occurring patterns contain genes in
different pathways, whereas most mutually exclusive pairs
are in the same pathways. This result is consistent with the
idea that cancer progression can be viewed as a Darwinian
evolutionary process [45], [46]. Mutations of two genes
participating in the same pathway or biological process
rarely confer a significant selective advantage compared to
the single mutation. By contrast, if the genes participate
in different pathways or functions, their mutations may
provide an additive or even synergistic role in conferring
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Fig. 1. An overview of the methods to discover driver pathways or core modules based on mutual exclusivity. Given a mutation matrix obtained from
the DNA sequencing data, the methods of discovering driver pathways or core modules are classified into two types depending on whether they
use the prior knowledge or not.
TABLE 1
Brief Summary of Methods for Discovering Driver Pathways or Core Modules
Category Method Website Reference
Individual driver pathway
–Prior knowledge
PSMP NA1 [44]
MEMo http://cbio.mskcc.org/memo [43]
Mutex http://code.google.com/p/mutex [48]
–De novo identification
Dendrix http://compbio.cs.brown.edu/projects/dendrix/ [49]
MDPFinder http://page.amss.ac.cn/shihua.zhang/software.html [50]
ME NA [52]
RME http://brl.bcm.tmc.edu/rme/index.rhtml [53]
iMCMC NA [54]
SODP2 http://pitttransmed-tcga.dbmi.pitt.edu/mutuallyExclusive/ [55]
Cooperative pathways
CoMDP http://page.amss.ac.cn/shihua.zhang/software.html [60]
Multi-Dendrix http://compbio.cs.brown.edu/projects/multi-dendrix/ [61]
GAMToC3 http://sourceforge.net/p/melamedgamtoc [62]
LM4 NA [63]
Pan-cancer analysis
HotNet24 http://compbio.cs.brown.edu/projects/hotnet2/ [41]
MEMCover4 NA [66]
Several methods fall into multiple categories but are listed only once for simplicity.
1 NA: not applicable.
2 SODP uses GO annotations for differential expression genes.
3 GAMToC actually detects one gene set each time, in which some genes are mutually exclusive and some others are co-occurring.
4 LM, HotNet2 and MEMCover employ gene interaction networks.
4an advantage to the tumor. Therefore, one would expect
to observe a tendency of mutually exclusive mutations of
genes in the same pathway and the tendency of co-occurring
mutations of genes participating in different pathways. This
suggests mutual exclusivity can be a basic criterion or
constraint for identifying driver pathways in cancer.
3.2 Discovery of Individual Driver Pathway
3.2.1 Prior Knowledge-based Methods
As stated in the previous section, some prior gene inter-
action networks can be used for the task of identifying
driver pathways. The goal is to find a subnetwork in which
the genes have statistically significant mutually exclusive
mutations (Fig. 2).
MEMo
Ciriello et al. designed MEMo [43] to identify candidate
driver subnetworks with three properties: (1) the member
genes of a driver pathway are recurrently altered across
multiple patients; (2) the member genes tend to participate
in the same pathway or biological process, and (3) alteration
events within a driver pathway are mutually exclusive.
Specifically, this method consists of four steps. First, for
all the somatic mutations and copy number alterations
(CNAs) across the observed samples, three gene filters are
used to identify the statistically significantly mutated genes
and significant regions of interest with concordant mRNA
expressions which is represented as a binary event matrix.
Second, MEMo performs a global gene comparison to assess
the network proximity of two genes by assessing the num-
ber of their common neighbors based on prior pathway and
network knowledge. Notably, although two genes do not
connect each other, they can also be assessed as proximal
if they share a large number of common neighbors. Third,
a graph based on the pair proximity is built with an edge
between two genes if their proximity is high. MEMo ex-
tracts all maximal cliques from this graph, which represent
local clusters and may contain proteins of likely similar
biological functions. And fourth, each detected clique is
tested whether its member genes are mutually exclusive by
a Markov chain Monte Carlo permutation strategy. MEMo
has been effectively used in applications with moderate
numbers of mutated genes, but a limitation is that it is not
able to run on very large data (such as the pan-cancer data
set) [41], [48].
Mutex
Babur et al. introduced a novel statistical metric to quantify
the mutual exclusivity between more than two altered genes
[48]. By combining prior pathway knowledge with this
statistic, they developed a new approach (Mutex) to identify
groups of mutually exclusively altered genes that have a
common downstream target. Specifically, they first collected
three interaction databases to obtain a large aggregated
pathway model of human signaling processes. Then they
employed a greedy algorithm by initializing a group with
an altered gene as a seed, and greedily expanding it with
the next best candidate gene until reaching a stop condition
to obtain a group with a score. In each step after adding a
candidate, the members still have a common downstream
target gene that can be reached without traversing any non-
member genes. Finally, they performed a permutation test
to control the false discovery rate (FDR) in the resulting
groups.
They have applied it to 17 different TCGA cancer
datasets and identified multiple significantly altered gene
groups. They also validated the efficiency of their method by
comparing it with existing methods on simulated datasets.
According to the principle of this method, all group mem-
bers are required to be directly linked on the network.
Extending this work by allowing non-member linker nodes
can detect more distant mutual exclusivity relations. How-
ever, this will be challenging because of the extended search
space and the reduced statistical power due to multiple
hypothesis testing [48].
3.2.2 De Novo Identification Methods
For these approaches stated above, prior knowledge such
as interactions between genes/proteins or known path-
ways are required. However, this kind of knowledge is
far from completeness now. Restricting attention to such
information limits the discovery of novel combinations of
mutated genes. To identify more driver pathways or gene
sets, it would be ideal to assess the significance of recurrent
mutations of all possible combinations of genes. But such
a de novo approach seems implausible because of the huge
number of combinations of mutated genes to test. Fortu-
nately, considering mutual exclusivity often possessed by
driver mutations, one can use this property as a criterion to
de novo detect driver gene sets (Fig. 3).
Dendrix
Besides the high exclusivity, high coverage is another key
characteristic of a driver pathway. In other words, a driver
pathway tends to be perturbed in a relatively large number
of patients. These two factors could dramatically limit the
search space and have been combined to identify de novo
driver pathways [49], [50]. Vandin et al. [49] introduced
a weight function W to reward coverage while penalize
overlap to get high exclusivity. Specifically, given a binary
mutation matrix A with m rows (samples) and n columns
(genes), the goal is to find a submatrix M of size m × k in
the mutation matrix A by maximizing the weight function
W :
W (M) = |Γ(M)| − ω(M) = 2|Γ(M)| −
∑
g∈M
|Γ(g)|, (1)
where Γ(g) = {i : Aig = 1} denotes the set of patients in
which gene g is mutated, Γ(M) = ∪g∈MΓ(g) and ω(M) =∑
g∈M |Γ(g)|− |Γ(M)|. |Γ(M)|measures the coverage ofM
and ω(M) measures the coverage overlap of M . This was
named as the maximum weight submatrix problem. Vandin
et al. [49] introduced a greedy algorithm and a Markov
chain Monte Carlo (MCMC) approach (called Dentrix) to
solve it. The MCMC approach samples from sets of genes
in proportion to their weight W (i.e., the gene sets with
high coverage and exclusivity have a higher probability to
be chosen). The authors have not paid more attention on
the greedy algorithm because of its requirement for a large
sample size and the hypothesis of gene independence [49].
They have applied the MCMC approach to three cancer
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Fig. 3. A schematic illustration of the methods for de novo identifying driver pathways. (A) Direct extraction methods based on the mutation matrix.
(a) Use a weight function (such as W ) and identify a gene set with high coverage and mutual exclusivity mutations [49], [50]. (b) Use the weight
function ‘total correlation’ and identify a gene set with the so called ‘exclusive or’ pattern [62]. (c) Use a probabilistic, generative model of mutual
exclusivity and identify the genes with similar mutation ratios [52]. (B) Network-based extraction from the mutation matrix. Build a weighted network
by using the algorithm Winnow; then extract core modules using a greedy search algorithm and significance test [53].
6mutation datasets and for some pre-assigned gene numbers
(i.e., k’s) they identified several driver gene sets relating
to the key cancer processes including Rb, p53, mTOR, and
MAPK signaling pathways. In most cases, one can used the
MCMC approach to get a gene set with a large value of the
weight W , but a possibility is that MCMC may be trapped
in a local solution because of the stochastic search process.
MDPFinder
Zhao et al. [50] developed a package MDPFinder (Mutated
Driver Pathway Finder) including an exact model and a
stochastic search algorithm to find mutated driver path-
ways. To address the issue of local optimality of Dendrix,
Zhao et al. first proposed a binary linear programming (BLP)
model to exactly solve the maximum weight submatrix
problem [50]. BLP can be employed to assess the accuracy
of other approximate and/or heuristic algorithms. Due to
the sparse structure of the mutation data, BLP is much faster
than Dendrix. Thus, it can be applied to the analysis of large-
scale mutation data sets.
Zhao et al. [50] also developed a genetic algorithm
(GA) to maximize more general and flexible weight func-
tions (including W ). In other words, it can be applied to
a weight function with different format or a new weight
function for incorporating other types of data (e.g., gene
expression data) to identify more biologically relevant gene
sets. The principle of integrating gene expression data comes
from that the expression profiles of gene pairs in the same
pathway usually have higher correlations than those in
different pathways [51]. This model can be employed to
distinguish the genes that have identical mutation profiles
or identify some gene sets with suboptimal score W but
with significant biological relevance.
ME
Cancer genomic alteration data may contain errors such as
measurement noise, false mutation calls and their misinter-
pretation, which can severely bias evaluation and ranking
of alteration patterns. Szczurek et al. [52] developed prob-
abilistic models to analyze cancer alteration data and then
to detect gene sets with mutually exclusive (ME) mutations.
They introduced two models: the first one is a probabilistic,
generative model of mutually exclusive patterns, which
considers observation errors; the second one is a null model
assuming independent alterations of genes. Comparing the
first model to the second one, a statistical test of mutual
exclusivity is derived. The generative model assumes that
genes in a module have equal chance to be altered. Thus, the
detected modules may tend to contain genes with similar
alteration ratios [48]. This may be improved by considering
the real mutation distribution.
RME
Miller et al. [53] developed the RME algorithm to detect
functional modules in tumors based on the patterns of
recurrent and mutually exclusive (RME) aberrations. First,
they filtered the mutation matrix to get genes satisfying a
pre-specifiedmutation frequency. Next, they used an online-
learning linear threshold algorithm called Winnow to score
each gene pair by exclusivity and created a weighted gene
network. Then, they obtained a set of candidate RME mod-
ules by a greedy local combinatorial search. Finally, they
employed an algorithmic significance test to evaluate the
significance of the RME patterns and thus determined the
significant RME modules. The RME algorithm only consid-
ers genes mutatedwith relatively high frequency which may
limit its effectiveness in identifying rare driver mutations.
iMCMC
Zhang et al. developed a network-based method to identify
Mutated Core Modules in Cancer (iMCMC) by integrating
somatic mutations, CNAs, and gene expressions [54]. They
have considered four gene features in the driver pathways
or core modules: high coverage, mutual exclusivity, strong
influence of a gene’s mutation on other genes and high
correlation of gene expressions. Specifically, they first ob-
tained a mutation matrix by merging somatic mutations and
CNAs, and constructed a weightedmutation network where
the vertex weight corresponds to gene coverage and the
edge weight corresponds to the mutual exclusivity between
gene pairs. They also generated a weighted expression net-
work from the expression matrix where the vertex and edge
weights correspond to the influence of a gene mutation on
other genes and the Pearson correlation of gene expressions,
respectively. Then they obtained an integrative network by
further combining these two networks, and identified the
most coherent subnetworks using an optimization model.
Finally, they extracted the core modules for tumors with
both significance and exclusivity tests. They applied iM-
CMC to real data to demonstrate that it can identify several
mutated core modules involved in known carcinogenesis
pathways.
SODP
We have to note that genes with mutually exclusive mu-
tations alone may be not sufficient to indicate they are in
a common pathway. Recently, Lu et al. [55] developed a
signal-oriented framework for discovering driver pathways
(named as SODP) by integrating genomic alteration data
and transcriptomic data from TCGA project. First, they
identified the perturbed cellular signals by grouping the
differentially expressed genes into functional groups sum-
marized by their Gene Ontology (GO) annotation. Next,
they constructed a bipartite graph consisting of tumors
and genes and searched for a densely connected subgraph.
Finally, they designed an exact algorithm to identify a set
of mutually exclusive gene alteration events which carries
strong information with respect to the perturbed signals
among the detected tumors. A main concern about SODP
is that the association between the detected gene alterations
and the perturbed signals may not have a causal relation-
ship which needs further experimental validation [55].
3.3 Identification of Cooperative Driver Pathways
All the above studies have focused on the identification of
individual driver pathways or core modules, where each
time a single group of genes with certain properties is
identified. However, cancer is a complex disease and mul-
tiple pathways with mutations are generally required for
carcinogenesis [33]. In fact, it has been recognized that
pathways often function cooperatively in cancer initiation
and progression [44], [56], [57]. Besides the combinatorial
patterns with co-occurring mutations identified by Yeang et
7al. [44], some other examples involved in lung squamous
cell carcinoma and GBM can be found in [58] and [59],
respectively.
Thus, investigating the complex collaboration among
different biological pathways and functional modules can
shed new lights on the understanding of the molecular
mechanisms of cancer formation and progression. In pre-
vious studies, incomplete prior knowledge on pathways
and/or interaction networks were utilized to determine
whether two or more pathways or modules are simulta-
neously perturbed in the same samples [44], [56], [59].
Recently, several de novo approaches have been developed
to discover collaborative pathways playing driver roles in
cancer initiation and development [60], [61], [62] (Fig. 4).
CoMDP
To investigate the collaboration among different path-
ways, a natural way is to investigate whether they are
almost simultaneously mutated in a large cohort of pa-
tients. Zhang et al. [60] introduced a weight function H
to investigate such co-occurring mutation patterns. They
further developed a mathematical programming model to
maximize H to de novo discover co-occurring mutated
driver pathways (CoMDP) in cancer. Specifically, for a
mutation matrix A, they considered two submatrices M
and N (which correspond to two gene sets or path-
ways). Given the coverage Γ(M) and Γ(N) of the two
gene sets, they defined two quantities: the common cov-
erage c(M,N) = |Γ(M)
⋂
Γ(N)|, and the union coverage
b(M,N) = |Γ(M)
⋃
Γ(N)|. They further defined the non-
shared coverage d(M,N) = b(M,N) − c(M,N), which
describes the extent of the mutation co-occurrence between
the two gene sets: the smaller the value d, the larger the co-
occurrence is. As stated in Eq. (1), ω(M) and ω(N) reflect
the exclusivity of M and N respectively. They introduced
the weight function H as follows:
H(M,N) = c(M,N)− d(M,N)− ω(M)− ω(N). (2)
Maximizing H implies the maximization of two types of
characteristics simultaneously: (1) the maximization of the
weight W for each individual pathway (i.e., high coverage
and high exclusivity; this can be realized by comprehen-
sively considering all the four terms on the right side of
Eq. (2)); and (2) the maximization of the inter-overlap be-
tween the pathway pair (guaranteed by the first two terms
on the right side of Eq. (2)). Moreover, CoMDP is an exact
method where the optimal set of pathways is obtained using
an efficient algorithm due to the sparse data structure. It
does not require any prior knowledge besides mutation pro-
files. They have demonstrated that CoMDP can get the exact
solution of gene sets with significant co-occurring mutations
using simulation data. They applied CoMDP to several real
biological data and discovered co-occurring driver path-
ways involved in several key biological processes such as
cell survival and protein synthesis. Furthermore, they also
proposed a modified form (named mod CoMDP) to model
the situations that a certain pathway has been previously
proven to play important roles in some cancers and one
wants to know whether there are other pathways with
cooperative effects in carcinogenesis [60].
Multi-Dendrix
Leiserson et al. [61] generalized Dentrix [49] and proposed
an approach, called Multi-Dendrix, to simultaneously iden-
tify multiple driver pathways in cancer. Multi-Dendrix was
designed to optimize the weight function which is a sum
of r quantities for the weight of r pathways. Each of the r
quantities corresponds to W in Eq. (1), so each of the gene
sets detected by Multi-Dendrix has high coverage and high
exclusivity. The authors also used a binary linear program-
ming to solve this problem, when r = 1, which is equivalent
to the one proposed in MDPFinder [50]. Applying Multi-
Dendrix to somatic mutations from GBM, breast cancer, and
lung cancer samples, the authors identified multiple sets
of genes involved in known important pathways for car-
cinogenesis. There is no considering the relationship among
the mutations of the gene sets, so the identified multiple
pathways by Multi-Dendrix are not necessarily co-occurring
[60].
GAMToC
Recently, Melamed et al. [62] introduced an information
theoretic method, called GAMToC, to identify combinations
of genomic alterations in cancer. GAMToC adopts the total
correlation (i.e., mutual information) to measure the differ-
ence between the joint uncertainty (or entropy) of a set of
variables (genes) and their individual uncertainties. The key
assumption is that the high total correlation suggests a joint
relationship among individual genes. Whereas, when there
is no joint relationship between the variables, the difference
will be zero.
A main property of GAMToC is that it detects a gene
set with jointly related mutation patterns each time. In
such a gene set, some genes may demonstrate high mu-
tual exclusivity, and some other genes may show high co-
occurrence. An example is an ‘exclusive or’ triplet of genes
where lesion of any two of the genes is enough to change
a phenotype, and the third adds no further advantage.
Although the genes display no mutual exclusivity or co-
occurrence characteristic, the total correlation of this three-
gene pattern is highly significant (Fig. 3A-b). The patterns
detected by GAMToC may be very complicated (Fig. 4),
indicating a complex cooperation among multiple biological
pathways, which needs further investigation.
LM
Although co-occurring or mutual exclusive gene alterations
have been explored in cancer, the understanding of molecu-
lar mechanisms in cancer initiation and progression remains
challenging. A basic problem is that pathways involved
in carcinogenesis are complex and interconnected without
clear boundary. Recently, Remy et al. developed a logical
model (LM) to explain mutually exclusive and co-occurring
genetic alterations (including somatic mutations, CNAs) in
bladder carcinogenesis [63]. First, by performing literature
search and data mining of four independent bladder can-
cer datasets, they identified nine patterns of co-occurrence
and mutual exclusivity in genetic alterations which are
involved in growth factor signaling pathways, cell cycle and
apoptosis. Next, they organized the interactions between
these genes into an influence network based on literature
analysis. Then they introduced a logical model and analyzed
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Fig. 4. A schematic illustration of the methods for the identification of cooperative driver pathways. Given the mutation matrix, CoMDP tends to
identify gene sets A and B, each of which has high mutual exclusivity. The co-occurrence of A and B implies likely cooperation between these two
pathways [60]. Multi-Dentrix may identify gene sets B and C, whose mutations are not necessarily co-occurring although each of them also has
high mutual exclusivity [61]. GAMToC may identify a gene set with complex mutational patterns (the gene set D). The first three genes are mutually
exclusive, and the others are their respective inversion [62].
it with the GINsim software. They validated this model
using a published mutant mice data. Moreover, it was used
to study the co-occurring and mutual exclusivity patterns,
suggesting this model allows one to formulate predictions
about conditions where combining genetic alterations bene-
fits carcinogenesis.
Indeed, by combining prior knowledge and mathemati-
cal modeling, LM can shed some lights on the mechanisms
leading to carcinogenesis. However, the model only includes
simplified representations of pathways, so in some cases the
interpretation of the results from the model analysis must
be done with further validation [63].
3.4 Pan-cancer Scale Analysis
With the accumulation of a large number of human can-
cer genomics data, the TCGA pan-cancer project surveyed
multi-platform aberration data in cancer samples from thou-
sands of cancer patients among 12 cancer types [64]. The
rich data provide a major opportunity to systematically
examine the similarities and differences among multiple
cancer types [64], [65]. Recently, several studies investigated
the mutual exclusivity and/or co-occurrence characteristics
across large TCGA pan-cancer mutation datasets [41], [66].
HotNet2
As mentioned earlier, HotNet2 [41] was designed to iden-
tify pathways and protein complexes based on pan-cancer
network analysis. HotNet2 employs a directed heat diffu-
sion model to detect mutated subnetworks without con-
sidering within-subnetwork mutual exclusivity and across-
subnetwork co-occurrence directly. Many pairs of detected
subnetworks exhibit significant co-occurrence across the
pan-cancer cohort or in individual cancer types. Compara-
tively, mutual exclusivity is typically possessed by the gene
mutations within a pathway but not across pathways. These
observations are consistent with previous studies [44], [49],
and also support the hypothesis that cancer cells harbor
multiple driver mutations that perturb multiple biological
functions [33].
MEMCover
As we have surveyed, mutual exclusivity has been adopted
for identifying driver pathways as a primary property of
gene mutations in cancer [43], [49], [50], [60]. However,
recent pan-cancer studies [52], [67] found that some mu-
tually exclusive genes are cancer type-specific. Thus, it is
necessary to recognize different mutual exclusivity classes
in pan-cancer analysis for driver pathway identification.
Kim et al. [66] classified mutual exclusivity into three
classes and carefully studied their properties. The first class
is ‘within tissue type exclusivity’ which means it is observed
only in one cancer type. The second class is called ‘across
tissue type exclusivity’, which is observed in more than one
tissue types. The last one is ‘between tissue type exclusivity’,
which is observed between tissue-specific genes. The first
two classes of mutually exclusive gene pairs have been
demonstrated to have a high possibility to be interacted
in the functional networks than those in the last class.
The method MEMCover was designed by combining across
tissue type exclusivity with interaction data to uncover pan-
cancer dysregulated pathways. The identified subnetworks
not only contain previously known pan-cancer dysregulated
modules but also reveal novel ones whose across cancer
role has not been explored well before. It is notable that the
selection of subnetworks in MEMCover is guided by mutual
9exclusivity, interaction network connectivity and sample
coverage. Thus, the subnetworks detected by MEMCover
do not necessarily contain mutually exclusive pairs [66].
4 CONCLUSION
The patterns of mutually exclusive genomic alterations pro-
vide important clue for understanding cancer initiation and
progression, and have widely been used to identify driver
pathways or modules in cancer in recent years. In fact,
besides the popular interpretation about mutual exclusivity,
i.e., alteration to a second gene within the same pathway
offers no further selective advantage, there is another expla-
nation on it, which says that the second alteration within
the same pathway actually leads to a disadvantage for the
cell, even results in cell death. This is referred to as syn-
thetic lethality [68], [69], which may provide an alternative
strategy for cancer treatment [70]. Although these two
hypotheses cannot be systematically distinguished based
on genomic data alone, the observed mutual exclusivity
provides evidence that the altered genes are functionally
linked, and most likely linked in a common pathway or
biological process.
Recent studies have developed a large number of al-
gorithms and models for the identification of driver path-
ways or core modules [40], [42], [43], [49], [50], [52], [53],
[54]. These methods have been applied to real data and
revealed key biological pathways such as p53, Rb and PI(3)K
pathways. Previous studies have provided evidence that
carcinogenesis is a complex process and the malignant trans-
formation from a normal cell to a tumor may be a highly co-
operative procedure involving synergy between pathways.
The methods for the identification of cooperative driver
pathways such as CoMDP [60], Multi-Dentrix [61] and
GAMToC [62] may be valuable to advance such analysis.
CoMDP can identify co-occurring mutated driver pathways,
while Multi-Dentrix can identify multiple pathways simul-
taneously without guaranteeing their co-occurrence in a
cohort of patients. GAMToC can detect a set of genes which
may contain multiple pathways, wherein some mutations
are exclusive, some are co-occurring, and some have the
‘exclusive or’ relationship or others. However, how various
cellular and physiological processes are coordinately altered
during the initiation and progression of cancer is still a
major challenge and need more deep investigations in the
future.
Here, we review the recent methods for identifying
driver genes, driver pathways in cancer using genomic al-
teration data. However, large-scale cancer genomics projects
provide huge numbers of multiple platform data including
gene expression, DNA methylation, microRNA expression,
protein expression, and clinical data [1], [2]. Different
kinds of data can provide different information for cancer
research. How to integrate diverse data into one model
or framework to investigate cancer initiation and progres-
sion is an important challenge. There have been a lot of
efforts in this direction. Besides the methods mentioned
above [54], [55], other approaches include PARADIGM [71]
which infers patient-specific pathway activities by using
multi-dimensional cancer genomics data, CONEXIC [72]
which integrates CNAs and gene expression data to identify
driver mutations and the processes that they influence,
and DriverNet [73] which was designed to relate genomic
aberrations to disrupted transcriptional patterns through
molecular interaction networks to identify driver genes in
cancer. Several integrative methods to decipher coherent
patterns have also been developed [74], [75], [76], [77],
[78], [79], [80], which may help to reveal clinically relevant
characteristics. More efforts are needed to comprehensively
integrate diverse cancer genomics data to uncover complex
mechanisms underlying oncogenesis.
Cancer displays large heterogeneity, but different types
of cancers may possess commonalities [64]. The rich cancer
genomics data provide a major opportunity to develop an
integrated picture of commonalities and differences across
tumor lineages, which is the main goal of the TCGA pan-
cancer project [64], [65], [81]. Although some comparative
studies among multiple cancer types have been developed
in recent years [41], [66], [81], [82], [83], more further
explorations are needed and more comprehensive results
are expected. Analysis of the molecular aberrations and their
functional roles across tumor types will be helpful to extend
effective therapies in one cancer type to others with a similar
genomic profile.
We also realize that along with more and more compu-
tational models and algorithms are developed to identify
driver pathways in cancer, a reasonable assessment or com-
parison of the performance of the approaches is of pressing
need. For driver gene identification methods, a comparative
strategy may be ranking the detected genes first by some
scores, and then investigating how many genes in the top
are in COSMIC or other cancer related database. But for
driver pathway approaches, a main issue is that pathways
involved in carcinogenesis are complex and interconnected
without clear boundary, so it is difficult to give a uniform
benchmark to evaluate the performance of these methods.
Even so, more efforts are expected to solve this challenge as
soon as possible because reasonable evaluation will benefit
one to develop more effective methods to decipher the
pathogenesis underlying cancer and thus will help under-
stand the molecular mechanism of carcinogenesis and make
effective personalized treatments for cancer patients.
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